Mackenzie Financial’s Design Therapeutics DSGN Stock Holding History

Mackenzie Financial’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.39M	Buy	+110,764	New	+$1.53M	﹤0.01%	1129

Other funds holding DSGN

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

Mackenzie Financial's DSGN Position: Q3 2026 in Review

Mackenzie Financial opened a new position in Design Therapeutics (DSGN) in Q3 2026: 110,764 shares worth $1.39M. The stake represents ﹤0.01% of the portfolio and ranks #1129 among its holdings.

42 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.

Mackenzie Financial held 110,764 shares of Design Therapeutics worth $1.39M as of Q3 2026.
Design Therapeutics was a new Mackenzie Financial position in Q3 2026.
Design Therapeutics made up ﹤0.01% of Mackenzie Financial's portfolio in Q3 2026, its #1129 holding.
42 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.

Based on Mackenzie Financial's 13F filing for Q3 2026, filed 2 Nov 2026.